Antivirals
Data from University of Texas Medical Branch at Galveston, Institute for Human Infections and Immunity provide new insights into antivirals
Published in Hepatitis Weekly, May 17th, 2010
A report, 'Development of novel therapies for hepatitis C,' is newly published data in Antiviral Research. "The current standard of care for the treatment of hepatitis C virus (HCV) infection is a combination of pegylated IFN and ribavirin (Peg-IFN/RBV). Because of the adverse effects associated with both IFN and ribavirin and because Peg-IFN/RBV provides only about a 45-50% sustained virological response (SVR, undetectable HCV RNA for greater than 24 weeks after cessation of therapy) in genotype 1-infected individuals, there is a need for more potent anti-HCV compounds with fewer adverse effects," scientists in the United States report.
"The twenty-first...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2010-05-17)
More Articles from Hepatitis Weekly
- Hepatitis B Antigens
Data from J. Simonetti et al provide new insights into hepatitis b antigens - Clinical Trial Research
Data from M.L. Shiffman et al provide new insights into clinical trial research - Biomedical Engineering
Findings from University of Modena broaden understanding of biomedical engineering - Virology
Investigators at National Institutes of Health target virology - Chronic Hepatitis B Virus
New chronic hepatitis B virus study findings recently were published by K. Nakahara and co-researchers - Chronic Hepatitis C Virus
New data from National Institutes of Health illuminate research in chronic hepatitis C virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
